Synthon chooses Avacta’s Optim 1000 for high throughput formulation studies
Apr.15, 2013 in
News
Pharmaceutical developers at Synthon, a global specialist in the development and manufacture of generic medicines, have chosen an Optim 1000 high throughput, micro-volume protein analysis system from Avacta for preliminary formulation studies.
Comments Off on Synthon chooses Avacta’s Optim 1000 for high throughput formulation studies